Endo Health new CEO suggests near-term sale unlikely, says Wells Fargo Wells Fargo believes the appointment of new CEO Rajiv De Silva suggests Endo Health does not intend to sell itself in the near-term, contrary to a Reuters report in January. Wells has a Market Perform rating on Endo shares.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo shares remain overvalued, says Cantor Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.